INJECTA™ - BIOAVAILABILITY ENHANCEMENT FOR INJECTABLES
ABITEC introduces new INJECTA™ parenteral grade lipid excipients to enable improved solubilization and permeation for injectable APIs. The INJECTA grade portfolio of products include: Captex® medium chain triglycerides and Capmul® mono-and di-glycerides of glycol esters fully analyzed and packaged for parenteral application.
INJECTA products provide improved solubility for BCS II and IV NCEs, aid in controlled release and go through processing in state-of-the-art facilities to ensure products of the highest quality. ABITEC purified lipid excipients meet applicable quality standards and comply with current and proposed monographs.
Please visit ABITEC at CPHI Worldwide in Barcelona at Stand # 4D56 to learn more about the INJECTA product line and request a sample. You may also download our brochure for more information at http://www.abiteccorp.com/right-on-target.
Contact details:
ABITEC CORPORATION
Website: www.abiteccorp.com
E-mail: acoulter@abiteccorp.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
